Literature DB >> 33335569

miR-218 inhibits glucose metabolism in non-small cell lung cancer via the NF-κB signaling pathway.

Wenxian Tian1, Xiangfei Yuan2, Yongna Song1, Jianxia Zhai1, Haixia Wei1, Linna Wang1, Dan Li1, Qiusheng Chen1.   

Abstract

High glucose metabolism is recognized as one of the hallmarks of cancer and increased expression levels of several key factors involved in glucose metabolism have been reported in non-small cell lung cancer (NSCLC). Previous studies showed that microRNA (miR)-218 is reduced in NSCLC, but its function in glucose metabolism in NSCLC is not fully understood. The present study aimed to investigate the effect of miR-218 on glucose metabolism in NSCLC cell lines and the underlying molecular mechanism. The present results suggested that miR-218 reduced glucose consumption, the mechanism of glycolysis and activity in the pentose phosphate pathway. In addition, glucose transporter 1 (GLUT1) was identified to be a direct target of miR-218, while overexpression of GLUT1 did not abolish the effect of miR-218 on glucose metabolism. The present results indicated that phosphorylation of NF-κB p65 was significantly decreased by miR-218 in NSCLC cells and that activation of NF-κB led to the inhibition of miR-218 regulation of glucose metabolism. In conclusion, the present results suggested that miR-218 downregulated glucose metabolism in NSCLC not only by directly targeting GLUT1, but also via the NF-κB signaling pathway.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  NF-κB; glycolysis; microRNA-218; non-small cell lung cancer; pentose phosphate pathway

Year:  2020        PMID: 33335569      PMCID: PMC7739860          DOI: 10.3892/etm.2020.9538

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  3 in total

1.  DACH1 as a multifaceted and potentially druggable susceptibility factor for kidney disease.

Authors:  Sandra Merscher; Christian Faul
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 19.456

Review 2.  miR-199a: A Tumor Suppressor with Noncoding RNA Network and Therapeutic Candidate in Lung Cancer.

Authors:  Wei Meng; Yanli Li; Binshu Chai; Xiaomin Liu; Zhongliang Ma
Journal:  Int J Mol Sci       Date:  2022-07-31       Impact factor: 6.208

Review 3.  Advances in the Biological Functions and Mechanisms of miRNAs in the Development of Osteosarcoma.

Authors:  Zihe Dong; Zhipeng Liao; Yonglin He; Chengye Wu; Zixiang Meng; Baolong Qin; Ge Xu; Zeyang Li; Tianxin Sun; Yuyan Wen; Guangjie Li
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.